Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52weeks

Journal of Diabetes Investigation

Volumn 4, Issue 2, 2013, Pages 174-181

  Kadowaki, Takashi ^a   Tajima, Naoko ^b   Odawara, Masato ^c   Nishii, Mikio ^e   Taniguchi, Tadaaki ^d   Ferreira, Juan Camilo Arjona ^f  

^a UNIVERSITY OF TOKYO   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d Merck Sharp Dohm Res Labs Japan   (Japan)

^e ONO PHARMACEUTICAL CO   (Japan)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Metformin; Sitagliptin; Type 2 diabetes

Indexed keywords

1,5 ANHYDROSORBITOL; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; AORTA DISSECTION; ARTICLE; COLON CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DUODENAL ULCER BLEEDING; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; JAPANESE; KINESIOTHERAPY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PNEUMONIA; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VERTEBRAL CANAL STENOSIS; VOMITING;

EID: 84878397107     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12001     Document Type: Article

References (22)

1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
2. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
3. Cook MN, Girman CJ, Stein PP, etal. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 2007; 24: 350-358.
4. Herman GA, Bergman A, Stevens C, etal. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
5. Aschner P, Kipnes MS, Lunceford JK, etal. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
6. Charbonnel B, Karasik A, Liu J, etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643.
7. Hermansen K, Kipnes M, Luo E, etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
8. Rosenstock J, Brazg R, Andryuk PJ, etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556-1568.
9. Vilsbøll T, Rosenstock J, Yki-Järvinen H, etal. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 167-177.
10. Kadowaki T, Tajima N, Odawara M, etal. Addition of sitagliptin, an oral, highly-selective dipeptidyl peptidase-4 inhibitor, improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetes 2011; 60(Suppl. 1): A279.
11. Hundal RS, Krssak M, Dufour S, etal. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-2069.
12. Migoya EM, Bergeron R, Miller JL, etal. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010; 88: 801-808.
13. Inzucchi SE, Bergenstal RM, Buse JB, etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
14. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23: 579-593.
15. Kuroe A, Fukushima M, Usami M, etal. Impaired β-cell function and insulin sensitivity in Japanese subjects wih normal glucose tolerance. Diabetes Res Clin Pract 2003; 59: 71-77.
16. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66S: S37-S43.
17. Mohan V, Yang W, Son HY, etal. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009; 83: 106-116.
18. Goldstein BJ, Feinglos MN, Lunceford JK, etal. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987.
19. Kashiwagi A, Kasuga M, Araki E, etal. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
20. Iwamoto Y, Tajima N, Kadowaki T, etal. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010; 12: 613-622.
21. Raz I, Chen Y, Wu M, etal. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537-550.
22. Barnett A, Allsworth J, Jameson K, etal. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007; 23: 1493-1507.